Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
LONDON - GSK plc (LSE/NYSE:GSK), in collaboration with iTeos Therapeutics, Inc., announced today the termination of their joint development program for belrestotug, an investigational anti-TIGIT monoclonal antibody. The decision follows interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which indicated that the compound did not meet the efficacy criteria necessary for further development.
Belrestotug was being studied as a potential treatment for various forms of cancer, but the recent findings from these studies have led to the conclusion of all ongoing research involving the drug. This includes the discontinuation of all study cohorts that were part of the belrestotug program.
As a company, GSK’s focus in oncology is directed towards improving the quality of life and survival rates for patients, with an emphasis on blood and women’s cancers. The company is also expanding its efforts into lung and gastrointestinal cancers, along with other solid tumors. Following the discontinuation of belrestotug, GSK plans to accelerate other priority programs, including the development of antibody-drug conjugates targeting B7-H3 and B7-H4, as well as IDRX-42, a selective KIT tyrosine kinase inhibitor.
GSK is a global biopharmaceutical entity that strives to advance the fight against diseases through a combination of science, technology, and talent. The company has advised investors that forward-looking statements made in this announcement are subject to risks and uncertainties, which may result in actual outcomes differing materially from projected results.
The information regarding the termination of the belrestotug development program is based on a press release statement issued by GSK. The company, headquartered in London, continues to be a major player in the pharmaceutical industry, committed to developing new treatments for a variety of diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.